// App-Quantinova.ai

716 : Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Researchers

Presenter

  • Florence Cymbalista

Principal Investigators

  • Dartigeas Caroline

  • Bruno Cazin

  • Olivier Tournilhac

  • Till M Seiler

  • Katja Zirlik

  • Jurgen Alt

  • Martin Sokler

  • Johannes Schetelig

  • Peter Dreger

  • Michael Hallek

  • Alain Delmer

  • Hartmut Dohner

  • Silja Mack

  • Andreas Buhler

  • Dirk Winkler

  • Thorsten Zenz

  • Raymonde Busch

  • Stefan Ibach

  • Sylvain Choquet

Medical Centers

  • Abteilung Innere Medizin II, Universitatsklinikum Tubingen, Tubingen, Germany

  • University of Ulm, Ulm, Germany

  • III.Med. Klinik fur Hamatologie / Onkologie, Johannes-Gutenberg-Universitat Mainz, Mainz, Germany

  • Medizinisch e Klinik und Poliklinik I, Universitaetskinikum Dresden, Dresden, Germany

  • Haematology, University of Freiburg, Freiburg, Germany,

  • Institute for Medical Statistics and Epidemiology, Technische Universitaet Muenchen, Munich, Germany

  • Clermont-Ferrand, CHU Estaing, Clermont Ferrand, France

  • Service Oncologie et Hematologie, CHU de Tours, Tours, France

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

  • Department of Internal Medicine III, Technical University of Munich, Munich, Germany

  • Service dHematologie Biologique, APHP La Pitie-Salpetriere, Paris, France

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Service -Hematologie Clinique, CHU de Rennes, Rennes, France

  • Internal Medicine III, University of Ulm, Ulm, Germany

  • Hopital Avicenne, Service -Hematologie Biologique, Bobigny, France

  • Department of Neurology Mazarin, Hopital Pitie-Salpetriere, Paris, France

Locations

  • France

  • Germany

Companies

  • WISP Wissenschaftlic

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Pulmonary embolism

  • Cytomegalovirus infection

  • Thrombocytopenia

  • Septic shock

  • Arrhythmia

  • Neutropenia

  • Venous thrombosis

  • Syncope

  • Anemia

  • Graft-versus-host disease

Biomarkers

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pegfilgrastim

  • Bendamustine

  • Alemtuzumab

  • Pentostatin

  • CI-825

  • fludarabine tablet

  • Cladribine

  • Rituximab

  • Allopurinol

  • TP53

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved